Namodenoson API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Namodenoson API 163042-96-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Namodenoson. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Namodenoson
- Synonyms:
- 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
- Cas Number:
- 163042-96-4
- DrugBank number:
- DB12885
- Unique Ingredient Identifier:
- Z07JR07J6C
General Description:
Namodenoson, identified by CAS number 163042-96-4, is a notable compound with significant therapeutic applications. Namodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.
Classification:
Namodenoson belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety, classified under the direct parent group Purine nucleosides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the Purine nucleosides class, specifically within the None subclass.
Categories:
Namodenoson is categorized under the following therapeutic classes: Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Purine Nucleosides, Purinergic Agents, Purinergic Agonists, Purinergic P1 Receptor Agonists, Purines, Ribonucleosides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Namodenoson is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
